Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): Impact of the inter-stages course on morbi-mortality and implications for management

التفاصيل البيبلوغرافية
العنوان: Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): Impact of the inter-stages course on morbi-mortality and implications for management
المؤلفون: A. Pequignot, Olivier Scatton, Valerio Lucidi, O. Soubrane, F.-R. Pruvot, Olivier Farges, Y.P. Le Treut, Safi Dokmak, J.-M. Regimbeau, R. Gauzolino, Stéphanie Truant, Vincent Donckier, M.-L. Blanleuil, René Adam, C. Castro Benitez, Raffaele Brustia, Alexis Laurent, C. Lim, Daniel Azoulay
المصدر: European Journal of Surgical Oncology (EJSO). 41:674-682
بيانات النشر: Elsevier BV, 2015.
سنة النشر: 2015
مصطلحات موضوعية: medicine.medical_specialty, business.industry, medicine.medical_treatment, Mortality rate, Biliary fistula, General Medicine, Perioperative, medicine.disease, Liver regeneration, Portal vein thrombosis, Surgery, Oncology, Ascites, medicine, Hepatectomy, medicine.symptom, Complication, business
الوصف: Background Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) was recently developed to induce rapid hypertrophy and reduce post-hepatectomy liver failure in patients with insufficient remnant liver volume (RLV). However, mortality rates >12% have been reported. This study aimed to analyze the perioperative course of ALPPS and to identify factors associated with morbi-mortality. Methods Between April 2011 and September 2013, 62 patients operated in 9 Franco-Belgian hepatobiliary centres underwent ALPPS for colorectal metastases (N = 50) or primary tumors, following chemotherapy (N = 50) and/or portal vein embolization (PVE; N = 9). Results Most patients had right (N = 31) or right extended hepatectomy (N = 25) (median RLV/body weight ratio of 0.54% [0.21–0.77%]). RLV increased by 48.6% [−15.3 to 192%] 7.8 ± 4.5 days after stage1, but the hypertrophy decelerated beyond 7 days. Stage2 was cancelled in 3 patients (4.8%) for insufficient hypertrophy, portal vein thrombosis or death and delayed to ≥9 days in 32 (54.2%). Overall, 25 patients (40.3%) had major complication(s) and 8 (12.9%) died. Fourteen patients (22.6%) had post-stage1 complication of whom 5 (35.7%) died after stage2. Factors associated with major morbi-mortality were obesity, post-stage1 biliary fistula or ascites, and infected and/or bilious peritoneal fluid at stage2. The latter was the only predictor of Clavien ≥3 by multivariate analysis (OR: 4.9; 95% CI: 1.227–19.97; p = 0.025). PVE did not impact the morbi-mortality rates but prevented major cytolysis that was associated with poor outcome. Conclusions The inter-stages course was crucial in determining ALPPS outcome. The factors of high morbi-mortality rates associated with ALPPS are linked to the technique complexity.
تدمد: 0748-7983
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::32c393a37b6e75f636ff10ac6a94a0acTest
https://doi.org/10.1016/j.ejso.2015.01.004Test
حقوق: CLOSED
رقم الانضمام: edsair.doi...........32c393a37b6e75f636ff10ac6a94a0ac
قاعدة البيانات: OpenAIRE